<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32019158</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle><i>Lactobacillus acidophilus</i> DDS-1 and <i>Bifidobacterium lactis</i> UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">363</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12020363</ELocationID><Abstract><AbstractText>This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, <i>L</i><i>actobacillus</i> <i>acidophilus</i> DDS-1 (1 &#xd7; 10<sup>10</sup> CFU/day) or <i>B</i><i>ifidobacterium</i> <i>animalis</i> subsp. <i>lactis</i> UABla-12 (1 &#xd7; 10<sup>10</sup> CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: -2.59 &#xb1; 2.07, p = 0.001; UABla-12: -1.56 &#xb1; 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p &lt; 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (-133.4 &#xb1; 95.19, p &lt; 0.001) and B. lactis UABla-12 (-104.5 &#xb1; 96.08, p &lt; 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martoni</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Shalini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vedic Lifesciences, 203 Morya Landmark1, New Link Road, Andheri W, Mumbai 400053, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyer</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="Y">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="Y">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">bowel habits</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>Christopher J. Martoni and Gregory Leyer are employees of UAS Laboratories but were not involved in the study conduct, data management or statistical analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32019158</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pii">nu12020363</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtmann G.J., Ford A.C., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Santos J., Vanner S.J., Vergnolle N., Zoetendal E.G., Quigley E.M. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305&#x2013;1318. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale H.F., Rasmussen S.H., Asiller &#xd6;.&#xd6;., Lied G.A. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients. 2019;11:2048. doi: 10.3390/nu11092048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092048</ArticleId><ArticleId IdType="pmc">PMC6769995</ArticleId><ArticleId IdType="pubmed">31480656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B., Patel N. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017;6:99. doi: 10.3390/jcm6110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P., Chey W.D., Harris L.A., Lacy B.E., Saito Y.A., Quigley E.M.M. ACG Task Force on Management of Irritable Bowel Syndrome American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018;113:1&#x2013;18. doi: 10.1038/s41395-018-0084-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0084-x</ArticleId><ArticleId IdType="pubmed">29950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:1&#x2013;6. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Didari T., Mozaffari S., Nikfar S., Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J. Gastroenterol. 2015;21:3072&#x2013;3084. doi: 10.3748/wjg.v21.i10.3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i10.3072</ArticleId><ArticleId IdType="pmc">PMC4356930</ArticleId><ArticleId IdType="pubmed">25780308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:1&#x2013;11. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M.R., Quigley E.M.M. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am. J. Gastroenterol. 2014;109:S2&#x2013;S26. doi: 10.1038/ajg.2014.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.187</ArticleId><ArticleId IdType="pubmed">25091148</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Evans M., Chow C.T., Chan L.S., Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J. Dig. Dis. 2019;20:435&#x2013;446. doi: 10.1111/1751-2980.12797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-2980.12797</ArticleId><ArticleId IdType="pmc">PMC6851827</ArticleId><ArticleId IdType="pubmed">31271261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakdaman M.N., Udani J.K., Molina J.P., Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - A randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr. J. 2016;15 doi: 10.1186/s12937-016-0172-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0172-y</ArticleId><ArticleId IdType="pmc">PMC4875742</ArticleId><ArticleId IdType="pubmed">27207411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerasimov S.V., Ivantsiv V.A., Bobryk L.M., Tsitsura O.O., Dedyshin L.P., Guta N.V., Yandyo B.V. Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: A randomized controlled trial. Eur. J. Clin. Nutr. 2016;70:463&#x2013;469. doi: 10.1038/ejcn.2015.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2015.171</ArticleId><ArticleId IdType="pubmed">26463725</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerasimov S.V., Vasjuta V.V., Myhovych O.O., Bondarchuk L.I. Probiotic supplement reduces Atopic Dermatitis in preschool children: A randomized, double-blind, placebo-controlled, clinical trial. Am. J. Clin. Dermatol. 2010;11:351&#x2013;361. doi: 10.2165/11531420-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11531420-000000000-00000</ArticleId><ArticleId IdType="pubmed">20642296</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Shinde T., Shastri M.D., Perera A.P., Tristram S., Martoni C.J., Gundamaraju R., Ahuja K.D.K., Ball M., Eri R. A human origin strain Lactobacillus acidophilus DDS-1 exhibits superior in vitro probiotic efficacy in comparison to plant or dairy origin probiotics. Int. J. Med. Sci. 2018;15:840&#x2013;848. doi: 10.7150/ijms.25004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.25004</ArticleId><ArticleId IdType="pmc">PMC6036100</ArticleId><ArticleId IdType="pubmed">30008595</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Shinde T., Gundamaraju R., Gondalia S.V., Karpe A.V., Beale D.J., Martoni C.J., Eri R. Lactobacillus acidophilus DDS-1 modulates the gut microbiota and improves metabolic profiles in aging mice. Nutrients. 2018;10:1255. doi: 10.3390/nu10091255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10091255</ArticleId><ArticleId IdType="pmc">PMC6165029</ArticleId><ArticleId IdType="pubmed">30200669</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Gundamaraju R., Shinde T., Perera A.P., Basheer W., Southam B., Gondalia S.V., Karpe A.V., Beale D.J., Tristram S., et al. Lactobacillus acidophilus DDS-1 modulates intestinal-specific microbiota, short-chain fatty acid and immunological profiles in aging mice. Nutrients. 2019;11:1297. doi: 10.3390/nu11061297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11061297</ArticleId><ArticleId IdType="pmc">PMC6627711</ArticleId><ArticleId IdType="pubmed">31181695</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagala R., Routray C. Clinical Case Study&#x2014;Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome. US Gastroenterol. Hepatol. Rev. 2011;7:1&#x2013;2.</Citation></Reference><Reference><Citation>Spiegel B.M.R., Bolus R., Harris L.A., Lucak S., Chey W.D., Sayuk G., Esrailian E., Lembo A., Karsan H., Tillisch K., et al. Characterizing abdominal pain in IBS: Guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment. Pharmacol. Ther. 2010;32:1192&#x2013;1202. doi: 10.1111/j.1365-2036.2010.04443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04443.x</ArticleId><ArticleId IdType="pmc">PMC4118306</ArticleId><ArticleId IdType="pubmed">20807217</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B., Bolus R., Harris L.A., Lucak S., Naliboff B., Esrailian E., Chey W.D., Lembo A., Karsan H., Tillisch K., et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: Results from the proof cohort. Aliment. Pharmacol. Ther. 2009;30:1159&#x2013;1170. doi: 10.1111/j.1365-2036.2009.04144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04144.x</ArticleId><ArticleId IdType="pmc">PMC2793273</ArticleId><ArticleId IdType="pubmed">19751360</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M.R., Bolus R., Agarwal N., Sayuk G., Harris L.A., Lucak S., Esrailian E., Chey W.D., Lembo A., Karsan H., et al. Measuring symptoms in the irritable bowel syndrome: Development of a framework for clinical trials. Aliment. Pharmacol. Ther. 2010;32:1275&#x2013;1291. doi: 10.1111/j.1365-2036.2010.04464.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04464.x</ArticleId><ArticleId IdType="pubmed">20955447</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake M.R., Raker J.M., Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2016;44:693&#x2013;703. doi: 10.1111/apt.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13746</ArticleId><ArticleId IdType="pubmed">27492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Drossman D.A., Frederick I.O., Dicesare J., Puder K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S., Williamson G. Perceived stress in a probability sample of the United States. Soc. Psychol. Heal. 1988:31&#x2013;67.</Citation></Reference><Reference><Citation>Ghoshal U.C., Abraham P., Bhatt C., Choudhuri G., Bhatia S.J., Shenoy K.T., Banka N.H., Bose K., Bohidar N.P., Chakravartty K., et al. Epidemiological and clinical profile of irritable bowel syndrome in India: Report of the Indian Society of Gastroenterology Task Force. Indian J. Gastroenterol. 2008;27:22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541934</ArticleId></ArticleIdList></Reference><Reference><Citation>Masudur Rahman M., Mahadeva S., Ghoshal U.C. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J. Gastroenterol. 2017;23:6788&#x2013;6801. doi: 10.3748/wjg.v23.i37.6788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i37.6788</ArticleId><ArticleId IdType="pmc">PMC5645613</ArticleId><ArticleId IdType="pubmed">29085223</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . Guidance for Industry: Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment. Food and Drug Administration; Silver Spring, MD, USA: 2012. pp. 32124&#x2013;32125.</Citation></Reference><Reference><Citation>Ford A.C., Moayyedi P. Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2010;32:144&#x2013;158. doi: 10.1111/j.1365-2036.2010.04328.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04328.x</ArticleId><ArticleId IdType="pubmed">20412064</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R.C. Problems and challenges in the design of irritable bowel syndrome clinical trials: Experience from published trials. Am. J. Med. 1999;107:91S&#x2013;97S. doi: 10.1016/S0002-9343(99)00086-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(99)00086-8</ArticleId><ArticleId IdType="pubmed">10588179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangel A.W. Study design issues in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2004;19:141&#x2013;142. doi: 10.1046/j.1365-2036.2003.01816.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01816.x</ArticleId><ArticleId IdType="pubmed">14687176</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L.E. Study design considerations for irritable bowel syndrome clinical trials. Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol. 2014;27:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188930</ArticleId><ArticleId IdType="pubmed">25330749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn S.D., Kaptchuk T.J., Park J.B., Nguyen L.T., Canenguez K., Nam B.H., Woods K.B., Conboy L.A., Stason W.B., Lembo A.J. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol. Motil. 2007;19:630&#x2013;637. doi: 10.1111/j.1365-2982.2007.00937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00937.x</ArticleId><ArticleId IdType="pubmed">17640177</ArticleId></ArticleIdList></Reference><Reference><Citation>Snapinn S.M., Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials. 2007;8:31. doi: 10.1186/1745-6215-8-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-8-31</ArticleId><ArticleId IdType="pmc">PMC2164942</ArticleId><ArticleId IdType="pubmed">17961249</ArticleId></ArticleIdList></Reference><Reference><Citation>European Food Safety Authority (EFSA) Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J. 2011;9:1984. doi: 10.2903/j.efsa.2011.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2011.1984</ArticleId><ArticleId IdType="pmc">PMC7009729</ArticleId><ArticleId IdType="pubmed">32625715</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay R., Singh A. Irritable Bowel Syndrome: The Indian Scenario. Med. Updat. 2013:255&#x2013;258.</Citation></Reference><Reference><Citation>Chong P.P., Chin V.K., Looi C.Y., Wong W.F., Madhavan P., Yong V.C. The microbiome and irritable bowel syndrome - A review on the pathophysiology, current research and future therapy. Front. Microbiol. 2019;10:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Gambaccini D., Stasi C., Urbano M.T., Marchi S., Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J. Gastroenterol. 2014;20:8807&#x2013;8820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112881</ArticleId><ArticleId IdType="pubmed">25083055</ArticleId></ArticleIdList></Reference><Reference><Citation>Simren M., Palsson O.S., Whitehead W.E. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr. Gastroenterol. Rep. 2017;19 doi: 10.1007/s11894-017-0554-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-017-0554-0</ArticleId><ArticleId IdType="pmc">PMC5378729</ArticleId><ArticleId IdType="pubmed">28374308</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778&#x2013;1783. doi: 10.1053/gast.2002.33579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2002.33579</ArticleId><ArticleId IdType="pubmed">12055584</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilarte M., Santos J., De Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203&#x2013;209. doi: 10.1136/gut.2006.100594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2006.100594</ArticleId><ArticleId IdType="pmc">PMC1856785</ArticleId><ArticleId IdType="pubmed">17005763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomax A.E., Pradhananga S., Sessenwein J.L., O&#x2019;Malley D. Bacterial modulation of visceral sensation: Mediators and mechanisms. Am. J. Physiol. Liver Physiol. 2019;317:G363&#x2013;G372. doi: 10.1152/ajpgi.00052.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00052.2019</ArticleId><ArticleId IdType="pubmed">31290688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007;13:35&#x2013;37. doi: 10.1038/nm1521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Palsson O.S., Maier D., Carroll I., Galanko J.A., Leyer G., Ringel Y. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: A double-blind study. J. Clin. Gastroenterol. 2011;45:518&#x2013;525. doi: 10.1097/MCG.0b013e31820ca4d6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31820ca4d6</ArticleId><ArticleId IdType="pmc">PMC4372813</ArticleId><ArticleId IdType="pubmed">21436726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Goldsmith J.R., Carroll I.M., Barros S.P., Palsson O., Jobin C., Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - A randomised clinical study. Aliment. Pharmacol. Ther. 2014;40:200&#x2013;207. doi: 10.1111/apt.12800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12800</ArticleId><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranuh R., Athiyyah A.F., Darma A., Risky V.P., Riawan W., Surono I.S., Sudarmo S.M. Effect of the probiotic lactobacillus plantarum is-10506 on bdnf and 5ht stimulation: Role of intestinal microbiota on the gut-brain axis. Iran. J. Microbiol. 2019;11:145&#x2013;150. doi: 10.18502/ijm.v11i2.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijm.v11i2.1077</ArticleId><ArticleId IdType="pmc">PMC6635314</ArticleId><ArticleId IdType="pubmed">31341569</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X. Impact of psychological stress on irritable bowel syndrome. World J. Gastroenterol. 2014;20:14126&#x2013;14131. doi: 10.3748/wjg.v20.i39.14126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i39.14126</ArticleId><ArticleId IdType="pmc">PMC4202343</ArticleId><ArticleId IdType="pubmed">25339801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakan D.B., Maji A., Sharma A.K., Saxena R., Pulikkan J., Grace T., Gomez A., Scaria J., Amato K.R., Sharma V.K. The unique composition of Indian gut microbiome, gene catalogue, and associated fecal metabolome deciphered using multi-omics approaches. Gigascience. 2019;8:1&#x2013;20. doi: 10.1093/gigascience/giz004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giz004</ArticleId><ArticleId IdType="pmc">PMC6394208</ArticleId><ArticleId IdType="pubmed">30698687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32635661</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness of Synbiotic Preparation Containing <i>Lactobacillus</i> and <i>Bifidobacterium</i> Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1999</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12071999</ELocationID><Abstract><AbstractText>The purpose of the randomized double-blind placebo-controlled trial was to assess the effectiveness of synbiotic preparation containing probiotic <i>Lactobacillus rhamnosus</i> FloraActive&#x2122; 19070-2, <i>Lactobacillus acidophilus</i> DSMZ 32418, <i>Bifidobacterium lactis</i> DSMZ 32269, <i>Bifidobacterium longum</i> DSMZ 32946, <i>Bifidobacterium bifidum</i> DSMZ 32403 and fructooligosaccharides in adult patients with diarrhea-dominant IBS (IBS-D). The study included eighty patients with moderate and severe IBS-D who were randomized to receive synbiotics or placebo for eight weeks. Finally, a total of sixty-eight patients finished the study. The primary endpoints included the assessment of the symptoms' severity with IBS symptom severity scale (IBS-SSS), an improvement of IBS global symptoms with Global Improvement Scale (IBS-GIS) and adequate relief of symptoms after four and eight weeks of therapy. Secondary endpoints, which were collected by telephone interviewers three times a week included the assessment of individual IBS symptoms and adverse events. Synbiotic treatment in comparison to placebo significantly improved IBS-GIS (<i>p</i> = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS (<i>p</i> = 0.042) and in domain-specific scores related to flatulence (<i>p</i> = 0.028) and bowel habit (<i>p</i> = 0.028) after four and eight weeks. Patients treated with synbiotics reported in weekly observations a significant amelioration in a feeling of incomplete bowel movements, flatulence, pain, stool pressure and diarrheal stools compared to those receiving placebo. There were no differences in adverse events between both groups. Concluding, the multi-strain synbiotic preparation was associated with a significant improvement in symptoms in IBS-D patients and was well-tolerated. These results suggest that the use of synbiotics offers a benefit for IBS-D patients. [Clinicaltrials.gov NCT04206410 registered 20 December 2019].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skrzyd&#x142;o-Radoma&#x144;ska</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prozorow-Kr&#xf3;l</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicho&#x17c;-Lach</LastName><ForeName>Halina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majsiak</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3638-9292</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Cardinal Stefan Wyszynski University, W&#xf3;ycickiego 1/3, 01-938 Warszaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bier&#x142;a</LastName><ForeName>Joanna B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5772-5091</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosikowski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Out-Patient Clinic, Konopnica 96L, 21-030 Motycz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczerbi&#x144;ski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantzel</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1897-0841</Identifier><AffiliationInfo><Affiliation>Biocare Copenhagen, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cukrowska</LastName><ForeName>Bo&#x17c;ena</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04206410</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>6/KBE/2018</GrantID><Agency>Biocare, Copenhagen, Denmark</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116580">fructooligosaccharide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="N">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069985" MajorTopicYN="N">Bifidobacterium bifidum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="N">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005414" MajorTopicYN="N">Flatulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052201" MajorTopicYN="N">Lacticaseibacillus rhamnosus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacterium</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">short chain fructooligosaccharides</Keyword><Keyword MajorTopicYN="N">synbiotics</Keyword></KeywordList><CoiStatement>B.C. has served as a speaker for Nutricia, Danone, Bayer, Apotex, Polpharma, and Mead Johnson. J.G. is the co-founder of Biocare Copenhagen, a company acquired by DSM Nutritional Products in 2017, but was not involved in conducting the study and data analyses. Other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32635661</ArticleId><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pii">nu12071999</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N. Engl. J. Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80. doi: 10.1007/s40273-015-0339-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-015-0339-y</ArticleId><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M., Farid M., Esrailian E., Talley J., Chang L. Is Irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am. J. Gastroenterol. 2010;105:848&#x2013;858. doi: 10.1038/ajg.2010.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.47</ArticleId><ArticleId IdType="pmc">PMC2887205</ArticleId><ArticleId IdType="pubmed">20197761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y., Pedrogo D.A.M., Kashyap P.C. Irritable bowel syndrome: A gut microbiota-related disorder? Am. J. Physiol.-Gastrointest. Liver Physiol. 2016;312:G52&#x2013;G62. doi: 10.1152/ajpgi.00338.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00338.2016</ArticleId><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A., Baker F.A., Mahamid M., Sbeit W., Khoury T. The Evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J. Clin. Med. 2020;9:685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivinus-N&#xe9;bot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut. 2013;63:744&#x2013;752. doi: 10.1136/gutjnl-2012-304066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-304066</ArticleId><ArticleId IdType="pubmed">23878165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusceddu M.M., Gareau M.G. Visceral pain: Gut microbiota, a new hope? J. Biomed. Sci. 2018;25:73. doi: 10.1186/s12929-018-0476-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0476-7</ArticleId><ArticleId IdType="pmc">PMC6182804</ArticleId><ArticleId IdType="pubmed">30309367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Gillilland M.G., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2017;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.R., Pimentel M. Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. Curr. Gastroenterol. Rep. 2006;8:305&#x2013;311. doi: 10.1007/s11894-006-0051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-006-0051-3</ArticleId><ArticleId IdType="pubmed">16836942</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:521&#x2013;530.e248. doi: 10.1111/j.1365-2982.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol.-Gastrointest. Liver Physiol. 2011;301:G799&#x2013;G807. doi: 10.1152/ajpgi.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P.M., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci. Rep. 2015;5:12693. doi: 10.1038/srep12693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12693</ArticleId><ArticleId IdType="pmc">PMC4523847</ArticleId><ArticleId IdType="pubmed">26239401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha M.Z., Khalil S.F.H. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020;20:e13&#x2013;e24. doi: 10.18295/squmj.2020.20.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId><ArticleId IdType="pmc">PMC7065695</ArticleId><ArticleId IdType="pubmed">32190365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:62. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 2004;5:169&#x2013;174. doi: 10.1111/j.1443-9573.2004.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1443-9573.2004.00176.x</ArticleId><ArticleId IdType="pubmed">15612887</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.-H., Rhee P.-L., Ko S.H., Joo N., Kim S.I., Kim C.-H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>A Drossman U., Dumitrascu D.L. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. 2006;15:237&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegler G., Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech. Coloproctology. 2001;5:163&#x2013;164. doi: 10.1007/s101510100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s101510100019</ArticleId><ArticleId IdType="pubmed">11875684</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagala R., Routray C. Clinical case study&#x2014;Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome. US Gastroenterol. Hepatol. Rev. 2011;7:36&#x2013;37.</Citation></Reference><Reference><Citation>Gerasimov S., Gantzel J., Dementieva N., Schevchenko O., Tsitsura O., Guta N., Bobyk V., Kaprus V. Role of Lactobacillus rhamnosus (FloraActive&#x2122;) 19070-2 and Lactobacillus reuteri (FloraActive&#x2122;) 12246 in Infant Colic: A Randomized Dietary Study. Nutrients. 2018;10:1975. doi: 10.3390/nu10121975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10121975</ArticleId><ArticleId IdType="pmc">PMC6315585</ArticleId><ArticleId IdType="pubmed">30551654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Longgui N., Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine. 2019;98:e16068. doi: 10.1097/MD.0000000000016068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016068</ArticleId><ArticleId IdType="pmc">PMC6635271</ArticleId><ArticleId IdType="pubmed">31277101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S., Ameen V., Bagby B., Shahan B., Jhingran P., Carter E. Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy. Dig. Dis. Sci. 2003;48:1317&#x2013;1323. doi: 10.1023/A:1024159226274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024159226274</ArticleId><ArticleId IdType="pubmed">12870789</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracie D.J., Ford A.C. Symbiotics in irritable bowel syndrome&#x2014;Better than probiotics alone? Curr. Opin. Clin. Nutr. Metab. Care. 2015;18:485&#x2013;489. doi: 10.1097/MCO.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000199</ArticleId><ArticleId IdType="pubmed">26107141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:139. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Colorectal Dis. 2012;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am. J. Gastroenterol. 2006;101:1288&#x2013;1294. doi: 10.1111/j.1572-0241.2006.00672.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00672.x</ArticleId><ArticleId IdType="pubmed">16771951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhnik Y., Raskine L., Simoneau G., Paineau D., Bornet F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. Nutr. J. 2006;5:8. doi: 10.1186/1475-2891-5-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2891-5-8</ArticleId><ArticleId IdType="pmc">PMC1448190</ArticleId><ArticleId IdType="pubmed">16569219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T., Iwasaki Y., Nakayama K., Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J. Nutr. Sci. Vitaminol. 2003;49:414&#x2013;421. doi: 10.3177/jnsv.49.414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3177/jnsv.49.414</ArticleId><ArticleId IdType="pubmed">14974732</ArticleId></ArticleIdList></Reference><Reference><Citation>Paineau D., Payen F., Panserieu S., Coulombier G., Sobaszek A., Lartigau I., Brabet M., Galmiche J.-P., Tripodi D., Sacher-Huvelin S., et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br. J. Nutr. 2008;99:311&#x2013;318. doi: 10.1017/S000711450779894X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S000711450779894X</ArticleId><ArticleId IdType="pubmed">17697398</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpiroz F., DuBray C., Bernalier-Donadille A., Cardot J.M., Accarino A., Serra J., Wagner A., Respondek F., Dapoigny M. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: A randomized, double blind, placebo controlled study. Neurogastroenterol. Motil. 2016;29:e12911. doi: 10.1111/nmo.12911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12911</ArticleId><ArticleId IdType="pubmed">27477485</ArticleId></ArticleIdList></Reference><Reference><Citation>Basturk A., Artan R., Y&#x131;lmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk. J. Gastroenterol. 2020;27:439&#x2013;443. doi: 10.5152/tjg.2016.16301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2016.16301</ArticleId><ArticleId IdType="pubmed">27782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin M.F., Rani R.A., Tamil A.M., Mokhtar N.M., Ali R.A.R. Effectiveness of sterilized symbiotic drink containing Lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Dig. Dis. Sci. 2019;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38658619</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>9478</StartPage><MedlinePgn>9478</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9478</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-60029-2</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is frequently linked with coexisting mental illnesses. Our previous study discovered that 32.1% of IBS patients had subthreshold depression (SD), placing them at higher risk of developing major depression. Gut microbiota modulation through psychobiotics was found to influence depression via the gut-brain axis. However, the efficacy of lessening depression among IBS patients remains ambiguous. The study's aim was to investigate the roles of cultured milk drinks containing 10<sup>9</sup>&#xa0;cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 on depression and related variables among IBS participants with SD. A total of 110 IBS participants with normal mood (NM) and SD, were randomly assigned to one of four intervention groups: IBS-NM with placebo, IBS-NM with probiotic, IBS-SD with placebo, and IBS-SD with probiotic. Each participant was required to consume two bottles of cultured milk every day for a duration of 12&#xa0;weeks. The following outcomes were assessed: depression risk, quality of life, the severity of IBS, and hormonal changes. The depression scores were significantly reduced in IBS-SD with probiotic and placebo from baseline (p&#x2009;&lt;&#x2009;0.001). Only IBS-SD with probiotic showed a significant rise in serotonin serum levels (p&#x2009;&lt;&#x2009;0.05). A significantly higher life quality measures were seen in IBS-SD with probiotic, IBS-SD with placebo, and IBS-NM with placebo (p&#x2009;&lt;&#x2009;0.05). All groups, both placebo and probiotic, reported significant improvement in IBS severity post-intervention with a higher prevalence of remission and mild IBS (p&#x2009;&lt;&#x2009;0.05). Dual strains lactobacillus-containing cultured milk drink via its regulation of relevant biomarkers, is a potential anti-depressive prophylactic agent for IBS patients at risk.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarkawi</LastName><ForeName>Marlynna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja Ali</LastName><ForeName>Raja Affendi</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>School of Medical and Life Sciences, Sunway University, Sunway City, 47500, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul Wahab</LastName><ForeName>Norhazlina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul Rathi</LastName><ForeName>Norshafila Diana</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mokhtar</LastName><ForeName>Norfilza Mohd</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia. norfilza@ppukm.ukm.edu.my.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. norfilza@ppukm.ukm.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FF-2019-064</GrantID><Agency>Cotra Enterprise Sdn Bhd</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043302" MajorTopicYN="N">Cultured Milk Products</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008892" MajorTopicYN="N">Milk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007778" MajorTopicYN="N">Lactobacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069980" MajorTopicYN="N">Lacticaseibacillus paracasei</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Functional gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">Gut-brain axis</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38658619</ArticleId><ArticleId IdType="pmc">PMC11043363</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-60029-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-60029-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riddle MS, Welsh M, Porter CK, Nieh C, Boyko EJ, Gackstetter G, et al. The epidemiology of irritable bowel syndrome in the US military: Findings from the Millennium Cohort Study. Am. J. Gastroenterol. 2016;111(1):93. doi: 10.1038/ajg.2015.386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2015.386</ArticleId><ArticleId IdType="pmc">PMC4759150</ArticleId><ArticleId IdType="pubmed">26729548</ArticleId></ArticleIdList></Reference><Reference><Citation>Icenhour A, Witt ST, Elsenbruch S, Low&#xe9;n M, Engstr&#xf6;m M, Tillisch K, et al. Brain functional connectivity is associated with visceral sensitivity in women with irritable bowel syndrome. NeuroImage Clin. 2017;15:449&#x2013;457. doi: 10.1016/j.nicl.2017.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.06.001</ArticleId><ArticleId IdType="pmc">PMC5470568</ArticleId><ArticleId IdType="pubmed">28649489</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP, Self MM, Czyzewski DI, Cejka S, Swank PR, Shulman RJ. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol. Motil. 2016;28(3):443&#x2013;448. doi: 10.1111/nmo.12738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12738</ArticleId><ArticleId IdType="pmc">PMC4760857</ArticleId><ArticleId IdType="pubmed">26690980</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5(10):908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J. Gastroenterol. 2017;23(37):6788. doi: 10.3748/wjg.v23.i37.6788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i37.6788</ArticleId><ArticleId IdType="pmc">PMC5645613</ArticleId><ArticleId IdType="pubmed">29085223</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee KA, Gonlachanvit S, Ghoshal UC, Chua AS, Miwa H, Wu J, et al. Second Asian consensus on irritable bowel syndrome. J. Neurogastroenterol. Motil. 2019;25(3):343. doi: 10.5056/jnm19041.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm19041</ArticleId><ArticleId IdType="pmc">PMC6657923</ArticleId><ArticleId IdType="pubmed">31327218</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhao D, Qi Q, Long X, Li Y, Wang P, et al. Nr2b-containing nmda receptors contribute to diarrhea-predominant irritable bowel syndrome. Oncotarget. 2018;11:5.</Citation></Reference><Reference><Citation>Lee C, Doo E, Choi JM, Jang SH, Ryu HS, Lee JY, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: Systematic review and meta-analysis. J. Neurogastroenterol. Motil. 2017;23(3):349. doi: 10.5056/jnm16220.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16220</ArticleId><ArticleId IdType="pmc">PMC5503284</ArticleId><ArticleId IdType="pubmed">28672433</ArticleId></ArticleIdList></Reference><Reference><Citation>Batabyal A, Bhattacharya A, Thaker M, Mukherjee S. A longitudinal study of perceived stress and cortisol responses in an undergraduate student population from India. PLoS ONE. 2021;16(6):e0252579. doi: 10.1371/journal.pone.0252579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252579</ArticleId><ArticleId IdType="pmc">PMC8177861</ArticleId><ArticleId IdType="pubmed">34086754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar NM, Bahrudin MF, Abd Ghani N, Abdul Rani R, Raja Ali RA. Prevalence of subthreshold depression among constipation-predominant irritable bowel syndrome patients. Front. Psychol. 2020;6(11):1936. doi: 10.3389/fpsyg.2020.01936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.01936</ArticleId><ArticleId IdType="pmc">PMC7423989</ArticleId><ArticleId IdType="pubmed">32849137</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi C, Nisita C, Cortopassi S, Corretti G, Gambaccini D, De Bortoli N, et al. Subthreshold psychiatric psychopathology in functional gastrointestinal disorders: can it be the bridge between gastroenterology and psychiatry? Gastroenterol. Res. Pract. 2017;30:2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682902</ArticleId><ArticleId IdType="pubmed">29213280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Peng X, Song X, Long J, Wang C, Zhang C, et al. The prevalence and risk of developing major depression among individuals with subthreshold depression in the general population. Psychol. Med. 2022;14:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10277767</ArticleId><ArticleId IdType="pubmed">35156595</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeuring HW, Comijs HC, Deeg DJ, Stek ML, Huisman M, Beekman AT. Secular trends in the prevalence of major and subthreshold depression among 55&#x2013;64-year olds over 20 years. Psychol. Med. 2018;48(11):1824&#x2013;1834. doi: 10.1017/S0033291717003324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291717003324</ArticleId><ArticleId IdType="pubmed">29198199</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi P, Worth C, Zenitsky G, Jin H, Sambamurti K, Anantharam V, et al. Mechanistic insights into gut microbiome dysbiosis-mediated neuroimmune dysregulation and protein misfolding and clearance in the pathogenesis of chronic neurodegenerative disorders. Front. Neurosci. 2022;16:1. doi: 10.3389/fnins.2022.836605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.836605</ArticleId><ArticleId IdType="pmc">PMC8914070</ArticleId><ArticleId IdType="pubmed">35281490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11(8):506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J. Affect. Disord. 2016;15(202):254&#x2013;257. doi: 10.1016/j.jad.2016.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.05.038</ArticleId><ArticleId IdType="pubmed">27288567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet SM, Palsson O, Whitehead WE, Barrow DA, T&#xf6;rnblom H, &#xd6;hman L, et al. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterol. Motil. 2018;30(10):e13378. doi: 10.1111/nmo.13378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13378</ArticleId><ArticleId IdType="pubmed">29797382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie R, Jiang P, Lin LI, Jiang J, Yu B, Rao J, et al. Oral treatment with Lactobacillus reuteri attenuates depressive-like behaviors and serotonin metabolism alterations induced by chronic social defeat stress. J. Psychiatr. Res. 2020;1(122):70&#x2013;78. doi: 10.1016/j.jpsychires.2019.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.12.013</ArticleId><ArticleId IdType="pubmed">31927268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-na&#xef;ve patients with major depression. PLoS ONE. 2018;13(6):e0197267. doi: 10.1371/journal.pone.0197267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197267</ArticleId><ArticleId IdType="pmc">PMC5983476</ArticleId><ArticleId IdType="pubmed">29856741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar N, Jaafar N, Alfian E, Rathi NM, Rani RA, Ali RR. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastro Enterol. Belg. 2021;1(84):585&#x2013;591. doi: 10.51821/84.4.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.51821/84.4.009</ArticleId><ArticleId IdType="pubmed">34965040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu YX, Wang Z, Wang XQ, Zhang JJ, Jiang RH, et al. Clinical characteristic and fecal microbiota responses to probiotic or antidepressant in patients with diarrhea-predominant irritable bowel syndrome with depression comorbidity: A pilot study. Chin. Med. J. 2019;132(03):346&#x2013;351. doi: 10.1097/CM9.0000000000000071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000071</ArticleId><ArticleId IdType="pmc">PMC6595810</ArticleId><ArticleId IdType="pubmed">30681503</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudzki L, Ostrowska L, Pawlak D, Ma&#x142;us A, Pawlak K, Waszkiewicz N, Szulc A. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;1(100):213&#x2013;222. doi: 10.1016/j.psyneuen.2018.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2018.10.010</ArticleId><ArticleId IdType="pubmed">30388595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult&#xae;) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18(1):1&#x2013;2. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalitsuradej, E., Sirilun, S., Chaiyasut, C., &amp; Sittiprapaporn, P. A preliminary study on effect of lactobacillus paracasei hii01 on cortisol in fatigue subjects. In 2019 16th International Conference on Electrical Engineering/Electronics, Computer, Telecommunications and Information Technology (ECTI-CON) 2019 Jul 10 (pp. 466&#x2013;469). IEEE.</Citation></Reference><Reference><Citation>Ma T, Jin H, Kwok LY, Sun Z, Liong MT, Zhang H. Probiotic consumption relieved human stress and anxiety symptoms possibly via modulating the neuroactive potential of the gut microbiota. Neurobiol. Stress. 2021;1(14):100294. doi: 10.1016/j.ynstr.2021.100294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2021.100294</ArticleId><ArticleId IdType="pmc">PMC7816019</ArticleId><ArticleId IdType="pubmed">33511258</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: A randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr. Res. 2018;62:1. doi: 10.29219/fnr.v62.1218.</Citation><ArticleIdList><ArticleId IdType="doi">10.29219/fnr.v62.1218</ArticleId><ArticleId IdType="pmc">PMC6034030</ArticleId><ArticleId IdType="pubmed">29997457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448&#x2013;459. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11(2):395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam NT, Earleywine M. Validation of the Center for Epidemiologic Studies Depression Scale&#x2014;Revised (CESD-R): Pragmatic depression assessment in the general population. Psychiatry Res. 2011;186(1):128&#x2013;132. doi: 10.1016/j.psychres.2010.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2010.08.018</ArticleId><ArticleId IdType="pubmed">20843557</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome (development and validation of a new measure) Digest. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. Severity in irritable bowel syndrome: A Rome Foundation Working Team report. Off. J. Am. Coll. Gastroenterol. 2011;106(10):1749&#x2013;1759. doi: 10.1038/ajg.2011.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2011.201</ArticleId><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>Depression WH. Other common mental disorders: global health estimates. World Health Organization; 2017. p. 24.</Citation></Reference><Reference><Citation>Laterza L, Napoli M, Petito V, Scaldaferri F, Gaetani E, Gasbarrini A. Evaluation of tolerability and major factors affecting the adherence to probiotic therapy in patients with irritable bowel syndrome: A prospective, observational, real-life study. Minerva Med. 2021;1:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">34114438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaub AC, Schneider E, Vazquez-Castellanos JF, Schweinfurth N, Kettelhack C, Doll JP, et al. Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: A randomized controlled trial. Transl. Psychiatry. 2022;12(1):227. doi: 10.1038/s41398-022-01977-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-01977-z</ArticleId><ArticleId IdType="pmc">PMC9163095</ArticleId><ArticleId IdType="pubmed">35654766</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32(3):315&#x2013;320. doi: 10.1016/j.nut.2015.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2015.09.003</ArticleId><ArticleId IdType="pubmed">26706022</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome: A cross-sectional study in Norway. Health Qual. Life Outcomes. 2015;13(1):1&#x2013;9. doi: 10.1186/s12955-015-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-015-0311-8</ArticleId><ArticleId IdType="pmc">PMC4518561</ArticleId><ArticleId IdType="pubmed">26223784</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandru BA, Rat LA, Moldovan AF, Mihancea P, Mari&#x219; L. An open-label trial study of quality-of-life assessment in irritable bowel syndrome and their treatment. Medicina. 2022;58(6):763. doi: 10.3390/medicina58060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58060763</ArticleId><ArticleId IdType="pmc">PMC9230795</ArticleId><ArticleId IdType="pubmed">35744026</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yu X, Yu L, Tian F, Zhao J, Zhang H, et al. Lactobacillus plantarum CCFM8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: A randomized, double-blind, placebo-controlled, pilot clinical trial. Engineering. 2021;7(3):376&#x2013;385. doi: 10.1016/j.eng.2020.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.06.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Zhang M, Ren F, Ren Y, Li Y, et al. Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation in patients with depression: A randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(7):2238. doi: 10.3390/nu13072238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072238</ArticleId><ArticleId IdType="pmc">PMC8308326</ArticleId><ArticleId IdType="pubmed">34209804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. WJG. 2012;18(17):2067. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Maixent JM, Pons O, Sennoune SR, Sadrin S. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome: Results from the LAPIBSS trial: Future objectives. Cell. Mol. Biol. 2020;66(3):211&#x2013;214. doi: 10.14715/cmb/2020.66.3.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.14715/cmb/2020.66.3.34</ArticleId><ArticleId IdType="pubmed">32538776</ArticleId></ArticleIdList></Reference><Reference><Citation>Og&#x142;odek EA. Changes in the serum concentration levels of serotonin, tryptophan and cortisol among stress-resilient and stress-susceptible individuals after experiencing traumatic stress. Int. J. Environ. Res. Public Health. 2022;19(24):16517. doi: 10.3390/ijerph192416517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192416517</ArticleId><ArticleId IdType="pmc">PMC9779530</ArticleId><ArticleId IdType="pubmed">36554398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rode J, Edebol Carlman HM, K&#xf6;nig J, Hutchinson AN, Thunberg P, Persson J, et al. Multi-strain probiotic mixture affects brain morphology and resting state brain function in healthy subjects: An RCT. Cells. 2022;11(18):2922. doi: 10.3390/cells11182922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11182922</ArticleId><ArticleId IdType="pmc">PMC9496704</ArticleId><ArticleId IdType="pubmed">36139496</ArticleId></ArticleIdList></Reference><Reference><Citation>Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2011;105(5):755&#x2013;764. doi: 10.1017/S0007114510004319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114510004319</ArticleId><ArticleId IdType="pubmed">20974015</ArticleId></ArticleIdList></Reference><Reference><Citation>Norlin AK, Walter S, Theodorsson E, Tegelstrom V, Grodzinsky E, Jones MP, et al. Cortisol levels in hair are altered in irritable bowel syndrome-A case control study in primary care. J. Psychosom. Res. 2017;1(93):69&#x2013;75. doi: 10.1016/j.jpsychores.2016.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2016.12.009</ArticleId><ArticleId IdType="pubmed">28107896</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Front. Cardiovasc. Med. 2017;20(4):48. doi: 10.3389/fcvm.2017.00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2017.00048</ArticleId><ArticleId IdType="pmc">PMC5517399</ArticleId><ArticleId IdType="pubmed">28775986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YH, Wang H, Denou E, Ghia JE, Rossi L, Fontes ME, Bernier SP, Shajib MS, Banskota S, Collins SM, Surette MG. Modulation of gut microbiota composition by serotonin signaling influences intestinal immune response and susceptibility to colitis. Cell. Mol. Gastroenterol. Hepatol. 2019;7(4):709&#x2013;728. doi: 10.1016/j.jcmgh.2019.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2019.01.004</ArticleId><ArticleId IdType="pmc">PMC6462823</ArticleId><ArticleId IdType="pubmed">30716420</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahora IS, Tsouklidis N, Kumar R, Soni R, Khan S. How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome. Cureus. 2020;12(8):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505258</ArticleId><ArticleId IdType="pubmed">32968548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayob N, Muhammad Nawawi KN, Mohamad Nor MH, Raja Ali RA, Ahmad HF, Oon SF, et al. The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease. Biomedicines. 2023;11(2):640. doi: 10.3390/biomedicines11020640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020640</ArticleId><ArticleId IdType="pmc">PMC9953317</ArticleId><ArticleId IdType="pubmed">36831176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranadheera CS, Vidanarachchi JK, Rocha RS, Cruz AG, Ajlouni S. Probiotic delivery through fermentation: Dairy vs non-dairy beverages. Fermentation. 2017;3(4):67. doi: 10.3390/fermentation3040067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/fermentation3040067</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee A, Hodori NA, Tung YZ, Ooi PL, Latif SA, Isa HM, et al. Depression level and coping responses toward the movement control order and its impact on quality of life in the Malaysian community during the COVID-19 pandemic: A web-based cross-sectional study. Ann. Gen. Psychiatry. 2021;20(1):31. doi: 10.1186/s12991-021-00352-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12991-021-00352-4</ArticleId><ArticleId IdType="pmc">PMC8142880</ArticleId><ArticleId IdType="pubmed">34030704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Mohd Yunus WM, Badri SK, Panatik SA, Mukhtar F. The unprecedented movement control order (lockdown) and factors associated with the negative emotional symptoms, happiness, and work-life balance of Malaysian University students during the coronavirus disease (COVID-19) pandemic. Front. Psychiatr. 2021;11:566221. doi: 10.3389/fpsyt.2020.566221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.566221</ArticleId><ArticleId IdType="pmc">PMC7921154</ArticleId><ArticleId IdType="pubmed">33664679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin MF, Abdul Rani R, Tamil AM, Mokhtar NM, Raja Ali RA. Effectiveness of sterilized symbiotic drink containing Lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Digest. Dis. Sci. 2020;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee NH, Razalli NH, Mokhtar NM, Tan E, Ali RA. An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia. Intest. Res. 2022;20(1):124. doi: 10.5217/ir.2020.00050.</Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2020.00050</ArticleId><ArticleId IdType="pmc">PMC8831767</ArticleId><ArticleId IdType="pubmed">33472341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Z, Mok CZ, Majid HA, Mahadeva S. Early experience with a low FODMAP diet in Asian patients with irritable bowel syndrome. JGH Open. 2018;2(5):178&#x2013;181. doi: 10.1002/jgh3.12069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12069</ArticleId><ArticleId IdType="pmc">PMC6207042</ArticleId><ArticleId IdType="pubmed">30483586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31952938</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3562</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</Title><ISOAbbreviation>Dig Liver Dis</ISOAbbreviation></Journal><ArticleTitle>A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial.</ArticleTitle><Pagination><StartPage>534</StartPage><EndPage>540</EndPage><MedlinePgn>534-540</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dld.2019.12.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1590-8658(19)30959-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">In the absence of a well-established therapeutic approach, patients with irritable bowel syndrome seek alternative strategies such as probiotics.</AbstractText><AbstractText Label="AIMS">The current trial named LAPIBSS aimed to demonstrate the efficacy of a 2-strain mixture of Lactobacillus acidophilus to improve irritable bowel syndrome symptoms.</AbstractText><AbstractText Label="METHODS">Eighty patients diagnosed for irritable bowel syndrome were recruited to a multicentre, double-blinded, in parallel groups, placebo-controlled, randomized clinical trial. Patients were provided with a daily dose of two capsules containing either probiotics (5&#x202f;&#xd7;&#x202f;10<sup>9</sup>&#x202f;cfu/capsule) or placebo for 8 weeks. The primary outcome was abdominal pain score assessed with a 100-mm visual analogue scale. Secondary outcomes included scores of bloating, flatus and rumbling assessed with a 100-mm visual analogue scale, a composite score and bowel habits.</AbstractText><AbstractText Label="RESULTS">Abdominal pain score was significantly improved in both groups at weeks 4 and 8 (P&#x202f;&lt;&#x202f;0.0001), but no significant differences were found between groups at week 8 (19.0&#x202f;&#xb1;&#x202f;2.5 vs 25.1&#x202f;&#xb1;&#x202f;2.6, respectively; LS Means differences&#x202f;=&#x202f;6.0&#x202f;&#xb1;&#x202f;3.2; P&#x202f;=&#x202f;0.06). Significant differences between groups were observed for flatus score at week 4 (P&#x202f;=&#x202f;0.04) and week 8 (P&#x202f;=&#x202f;0.03) and composite score (P&#x202f;=&#x202f;0.04) at week 8.</AbstractText><AbstractText Label="CONCLUSIONS">The consumption of the 2-strain mixture of L. acidophilus over 8 weeks is safe and decreases significantly flatus and composite scores.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">EudraCT No 2008 A00844-51.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadrin</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IAPS Laboratory, University of Toulon, Toulon, France; Laboratoire Denel-Codifra, Le Chesnay, France. Electronic address: stephane.sadrin@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sennoune</LastName><ForeName>Souad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cellular Physiology and Molecular Biophysics, Texas Tech University Health Sciences Center, Lubbock, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gout</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical and Global Clinical Solutions, Ramonville-Saint-Agne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marque</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Capionis, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Rangueil University Hospital of Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinoune</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Qualilab, Olivet, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grillasca</LastName><ForeName>Jo&#xeb;l-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>IAPS Laboratory, University of Toulon, Toulon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>IAPS Laboratory, University of Toulon, Toulon, France; General Practice, Montady, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maixent</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>IAPS Laboratory, University of Toulon, Toulon, France; Department of Physiology, Faculty of Fundamental and Applied Sciences, University of Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2008 A00844-51</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Dig Liver Dis</MedlineTA><NlmUniqueID>100958385</NlmUniqueID><ISSNLinking>1590-8658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Functional gastrointestinal disorders</Keyword><Keyword MajorTopicYN="N">Lactic acid bacteria</Keyword><Keyword MajorTopicYN="N">Microbiota</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31952938</ArticleId><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pii">S1590-8658(19)30959-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28082816</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>48</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.</ArticleTitle><Pagination><StartPage>10631</StartPage><EndPage>10642</EndPage><MedlinePgn>10631-10642</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v22.i48.10631</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine the effects of <i>Lactobacillus acidophilus</i> NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized triple-blind trial, adult IBS volunteers who were recruited according to Rome III criteria received 10<sup>9</sup> or 10<sup>10</sup> colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score (IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk run-in period, after 4 and 12 wk of intervention, and after a 4-wk washout.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 340 of 391 randomized volunteers completed the trial. IBS-SSS improved over 12 wk of treatment in all treatment groups, decreasing by a mean &#xb1; SD of 44.0 &#xb1; 80.2, 50.8 &#xb1; 82.4, and 48.3 &#xb1; 72.2 in the placebo, active low-dose, and active high-dose groups, respectively. Similarly, secondary outcomes did not differ between treatment groups. However, in a post hoc analysis of volunteers with moderate to severe abdominal pain at baseline (VAS &gt; 35/100), the treatment significantly reduced the sensation of abdominal pain. Pain scores fell by 20.8 &#xb1; 22.8, 29.4 &#xb1; 17.9, and 31.2 &#xb1; 21.9 in the placebo, active low-dose, and active high-dose groups, respectively (<i>P</i> value for placebo <i>vs</i> combined active doses = 0.0460).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyra</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillil&#xe4;</LastName><ForeName>Markku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huttunen</LastName><ForeName>Teppo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe4;nnikk&#xf6;</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taalikka</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tennil&#xe4;</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarpila</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahtinen</LastName><ForeName>Sampo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouwehand</LastName><ForeName>Arthur C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veijola</LastName><ForeName>Lea</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, Arthur C Ouwehand, DuPont Nutrition and Health, Global Health and Nutrition Science, Danisco Sweeteners Oy, 02460 Kantvik, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011957">Receptors, Opioid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011957" MajorTopicYN="N">Receptors, Opioid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059265" MajorTopicYN="N">Visceral Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal pain</Keyword><Keyword MajorTopicYN="N">Functional bowel disorder</Keyword><Keyword MajorTopicYN="N">Intervention</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus acidophilus</Keyword><Keyword MajorTopicYN="N">Probiotic</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Symptom questionnaire</Keyword><Keyword MajorTopicYN="N">Visceral pain</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: Anna Lyra, Julia Tennil&#xe4;, Anneli Tarpila, Sampo Lahtinen, and Arthur C Ouwehand are present or former employees of the sponsor, DuPont Nutrition and Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28082816</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hillil&#xe4; MT, F&#xe4;rkkil&#xe4; MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther. 2004;20:339&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274671</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogsgaard LR, Engsbro AL, Bytzer P. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults &#x2264;50 years of age. Scand J Gastroenterol. 2013;48:523&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">23506174</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA. Guidance on the scientific requirements for health claims related to gut and immune function. EFSA. 2011;9:1984.</Citation></Reference><Reference><Citation>Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014;20:8859&#x2013;8866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112904</ArticleId><ArticleId IdType="pubmed">25083059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol. 2014;20:14105&#x2013;14125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202342</ArticleId><ArticleId IdType="pubmed">25339800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110:278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317767</ArticleId><ArticleId IdType="pubmed">25623659</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney RD, Johnson AC, O&#x2019;Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neurosci Ther. 2016;22:102&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492884</ArticleId><ArticleId IdType="pubmed">26662472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013;48:995&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">23964766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547&#x2013;1561; quiz 1546, 1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungin AP, Mulligan C, Pot B, Whorwell P, Agr&#xe9;us L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. Aliment Pharmacol Ther. 2013;38:864&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925990</ArticleId><ArticleId IdType="pubmed">23981066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014;20:8796&#x2013;8806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112883</ArticleId><ArticleId IdType="pubmed">25083054</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62:787&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351195</ArticleId><ArticleId IdType="pubmed">23474420</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. Aliment Pharmacol Ther. 2014;40:200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45:518&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372813</ArticleId><ArticleId IdType="pubmed">21436726</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31:218&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">19863495</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">18785988</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43:400&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT, Kerr CE, Jacobson EE, Hu R, Friedlander E, et al. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009;104:912&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707022</ArticleId><ArticleId IdType="pubmed">19293784</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbaniak G, Plous S.  Research Randomizer. 4.0 ed, 2012: Computer software. Available from:  https://www.randomizer.org/</Citation></Reference><Reference><Citation>Altermann E, Russell WM, Azcarate-Peril MA, Barrangou R, Buck BL, McAuliffe O, Souther N, Dobson A, Duong T, Callanan M, et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA. 2005;102:3906&#x2013;3912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554803</ArticleId><ArticleId IdType="pubmed">15671160</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza B, Slack T, Wong SW, Lam F, Muhlmann M, Koestenbauer J, Dark J, Newstead G. Randomized controlled trial of probiotics after colonoscopy. ANZ J Surg. 2015 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">26183594</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs CE, R&#xf6;yti&#xf6; H, Alhoniemi E, Fekete AA, Forssten SD, Hudjec N, Lim YN, Steger CJ, Yaqoob P, Tuohy KM, et al. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br J Nutr. 2014;111:1945&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">24661576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery IB, O&#x2019;Toole PW, &#xd6;hman L, Claesson MJ, Deane J, Quigley EM, Simr&#xe9;n M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">22180058</ArticleId></ArticleIdList></Reference><Reference><Citation>Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther. 2012;35:350&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">22176384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment Pharmacol Ther. 2014;40:51&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner JM, Jaccard J, Keefer L, Firth R, Carosella AM, Sitrin M, Brenner D. The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil. 2014;26:1802&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4247164</ArticleId><ArticleId IdType="pubmed">25424582</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpiroz F, Guyonnet D, Donazzolo Y, Gendre D, Tanguy J, Guarner F. Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. J Clin Gastroenterol. 2015;49:e64&#x2013;e70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495859</ArticleId><ArticleId IdType="pubmed">25014236</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>